Strides Pharma Science
Indian generic drug maker selling affordable medicines across the US, Europe, and Africa.
On the record
Checkpoint: Q1 FY27 earnings call, first look at tariff and Sandoz-Africa impact
The call
Strides makes money today, but its next few years turn on FDA inspection results and whether US tariffs on Indian generics actually bite after 2028.
Strides Pharma makes generic copies of brand-name medicines and sells them globally, especially in Africa and the United States. It is hard to copy because it has FDA approvals and manufacturing licenses that take years to earn, but it is easy to replace because larger Indian competitors like Sun Pharma, Cipla, and Dr. Reddy's make the same drugs at similar costs and already have those same approvals. The company's future depends on two things outside its control: whether the U.S. government raises tariffs on imported drugs after 2028, which could hurt American sales, and whether it grows its Africa business fast enough to make up the difference if that happens.
Why
01
AI pressure: None apparent. AI drug-discovery tools speed up branded R&D, not generic manufacturing, so this business sits outside that fight. Could AI do the core job? Unlikely.
02
Bigger players: Sun Pharma, Cipla, Dr. Reddy's, Aurobindo, Lupin. Bigger Indian generics makers already sell into the same US and African markets with more scale and more ANDAs. Could a giant copy it? Yes, easily.
03
What protects it. FDA-approved manufacturing sites, PEPFAR and WHO prequalification, and distribution reach into 50 countries that smaller rivals lack.
What would change this call
FDA re-inspection outcome at Bengaluru or Chestnut Ridge within 12 months. Shows whether compliance issues (Form 483, VAI) escalate to a warning letter or import alert.
Africa/SSA revenue share reported in FY27 and FY28 segment splits, starting Q1 FY27 call July 31, 2026. Shows whether Africa growth is offsetting US tariff exposure as the tariff grace period ends Aug 2028.
Closing and integration progress of the Sandoz Africa deal (~Sept 2026). Shows whether Strides can scale Africa distribution fast enough to matter before tariffs bite.
Africa/SSA revenue share reported in FY27 and FY28 segment splits, starting Q1 FY27 call July 31, 2026. Shows whether Africa growth is offsetting US tariff exposure as the tariff grace period ends Aug 2028.
Closing and integration progress of the Sandoz Africa deal (~Sept 2026). Shows whether Strides can scale Africa distribution fast enough to matter before tariffs bite.
Key numbers
- FY26 revenue ₹48,587 million, up 6.4% YoY
- FY26 EBITDA margin 17.6%
- Sandoz Africa brand deal: $12 million upfront
Named risks
- US tariff escalation to 100% then 200% on imported generics starting after August 2028.
- FDA Form 483 with 5 observations at Bengaluru facility, May 2026, could lead to further action.
- Chestnut Ridge, NY facility classified VAI following December 2025 FDA inspection.
- Heavy revenue reliance on US market exposed to tender-based pricing and tariff risk.
- Integration risk on pending Sandoz Africa deal expected to close by Q2 FY27.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Sun Pharma | contesting | Larger-scale Indian generics peer with more mindshare, per sector coverage dated 2026-07-22 |
| Cipla | contesting | Direct competitor in regulated US and institutional generics markets |
| Dr. Reddy's Laboratories | contesting | Comparable scale in US generics exposure amid 2026-07 tariff selloff |
| Aurobindo Pharma | contesting | Named alongside Strides in US tariff exposure coverage, 2026-07-22 |
| Lupin | contesting | Peer in same tender-based generics pricing environment |
| Sandoz AG | gaining on | Strides acquired 18 Sandoz branded generic brands in Sub-Saharan Africa, March 2026, targeting top-5 SSA position |
Questions people ask
- Is Strides Pharma Science profitable in 2026?
- Yes. Strides reported FY26 (year ended March 31, 2026) operational PAT of ₹5,181 million, up 50% year over year, on consolidated revenue of ₹48,587 million and an EBITDA margin of 17.6%. The board recommended a final dividend of ₹5 per share, per its May 18, 2026 earnings presentation.
- Could AI replace Strides Pharma's manufacturing business?
- No. Strides' core business is physical, regulated generic drug manufacturing across roughly 15 GMP facilities in six countries, requiring ANDA approvals and FDA/WHO compliance. These regulatory and physical-asset moats are not replicable by AI models; the company's more AI-exposed digital/GCC unit, Pivot Path, was divested in June-July 2026.
- Who is Strides Pharma Science's biggest competitor?
- Strides competes directly against larger-scale Indian generics majors: Sun Pharma, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma, and Lupin, all of which operate in the same regulated US and institutional markets with greater scale and mindshare than Strides as of mid-2026.
- Who owns Strides Pharma Science?
- Strides Pharma Science is a publicly listed company on NSE (STAR) and BSE (532531), with a market capitalization of about ₹94,016 million as of July 26, 2026. Founder Arun Kumar serves as Non-Executive Chairman, with Badree Komandur as MD and Group CEO.
- Will Trump's tariffs hurt Strides Pharma?
- On July 21-22, 2026, Trump announced a phased US tariff on imported generic drugs: 0% for two years from August 1, 2026, then 100%, then 200%. Strides derives major revenue from the US market, making this a significant near-term risk factor flagged by Indian pharma sector coverage.
- Is Strides Pharma Science expanding in Africa?
- Yes. In March 2026, Strides announced acquiring and in-licensing about 18 branded generic brands from Sandoz AG across Sub-Saharan Africa (Ghana, Nigeria, Kenya, Western Sahara) for $12 million upfront plus royalties, aiming to become a top-5 pharma player by sales in the region, with closing expected by Q2 FY27.
Timeline
- 2026-07-24Q1 FY27 earnings call scheduled for July 31, 2026; record date set for FY26 ₹5/share dividend
- 2026-07-21Trump announces phased US tariff on generic drugs: 0% for 2 years, then 100%, then 200%
- 2026-07-01Pivot Path (formerly Arco Lab GCC) majority stake sale to Ascent Capital completed
- 2026-06-29Strides sells ~65.05% stake in Pivot Path for ~₹100 crore, valuing it at ~₹230 crore
- 2026-05-20Bengaluru facility receives FDA Form 483 with 5 observations after inspection
- 2026-05-18FY26 results: revenue ₹48,587m, EBITDA ₹9,253m, PAT ₹5,181m, dividend ₹5/share
- 2026-03-17Strides announces $12M upfront Sandoz Africa branded-generics acquisition
- 2026-02-05Chestnut Ridge, NY facility classified Voluntary Action Indicated by FDA
- 2024-04-01Demerger of CDMO/soft-gelatin business into OneSource Specialty Pharma completed
- 2018-07-01Company renamed Strides Pharma Science from Strides Shasun
Revision history
26 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Q4 & FY26 Earnings Presentation (2026-05-18)
- gurufocus.com (2026-07-26)
- Trump's 200% tariff threat (2026-07-23)
- Strides Pharma Faces FDA Scrutiny (2026-05-21)
- Strides Pharma's Chestnut Ridge unit classified VAI by USFDA (2026-02-05)
- Strides Pharma Science Limited Closeout Letter (2023-05-23)
- Strides Pharma to acquire, in-license Sandoz generic brands (2026-03-17)
- Strides Pharma Sells Majority Stake in Pivot Path for Rs 100 Crore (2026-06-29)
- Strides Pharma Science Schedules Q1 Earnings Conference Call (2026-07-24)
- Moneycontrol (2024-09-25)
- Strides Pharma Achieves 17.2% Revenue Growth in FY25 (2025-05-23)
- Strides Pharma Science Number of Employees 2026 (2026-06-29)